93 related articles for article (PubMed ID: 809543)
41. The significance of the 3'-nontranslated region and E2 amino acid mutations in the virulence of Semliki Forest virus in mice.
Santagati MG; Määttä JA; Röyttä M; Salmi AA; Hinkkanen AE
Virology; 1998 Mar; 243(1):66-77. PubMed ID: 9527916
[TBL] [Abstract][Full Text] [Related]
42. Viral infection and resistance in immunosuppressed host. I. Activation patterns of silent arbovirus infections.
Mayer V
Acta Virol; 1972 Jul; 16(4):323-35. PubMed ID: 4403174
[No Abstract] [Full Text] [Related]
43. The virulence of original and derived strains of Semliki forest virus for mice, guinea-pigs and rabbits.
Bradish CJ; Allner K; Maber HB
J Gen Virol; 1971 Aug; 12(2):141-60. PubMed ID: 5123325
[No Abstract] [Full Text] [Related]
44. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis.
Amor S; Scallan MF; Morris MM; Dyson H; Fazakerley JK
J Gen Virol; 1996 Feb; 77 ( Pt 2 )():281-91. PubMed ID: 8627232
[TBL] [Abstract][Full Text] [Related]
45. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice.
Cabrera A; Sáez D; Céspedes S; Andrews E; Oñate A
Immunobiology; 2009; 214(6):467-74. PubMed ID: 19150742
[TBL] [Abstract][Full Text] [Related]
46. Isolation and preliminary characterization of Semliki Forest virus mutants with altered virulence.
Barrett PN; Sheahan BJ; Atkins GJ
J Gen Virol; 1980 Jul; 49(1):141-7. PubMed ID: 7420061
[TBL] [Abstract][Full Text] [Related]
47. Prevention of death in Semliki Forest virus-infected mice by administration of defective-interfering Semliki Forest virus.
Dimmock NJ; Kennedy SI
J Gen Virol; 1978 May; 39(2):231-42. PubMed ID: 650175
[TBL] [Abstract][Full Text] [Related]
48. The Semliki Forest virus E2 gene as a virulence determinant.
Santagati MG; Määttä JA; Itäranta PV; Salmi AA; Hinkkanen AE
J Gen Virol; 1995 Jan; 76 ( Pt 1)():47-52. PubMed ID: 7844541
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and protective efficacy of Semliki forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins.
Zheng M; Jin N; Liu Q; Huo X; Li Y; Hu B; Ma H; Zhu Z; Cong Y; Li X; Jin M; Zhu G
Virology; 2009 Aug; 391(1):33-43. PubMed ID: 19559453
[TBL] [Abstract][Full Text] [Related]
50. Protection of mice infected with a lethal dose of Semliki Forest virus by defective interfering virus: modulation of virus multiplication.
Barrett AD; Guest AR; Mackenzie A; Dimmock NJ
J Gen Virol; 1984 Nov; 65 ( Pt 11)():1909-20. PubMed ID: 6094709
[TBL] [Abstract][Full Text] [Related]
51. Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity.
Atkins GJ; Sheahan BJ; Dimmock NJ
J Gen Virol; 1985 Mar; 66 ( Pt 3)():395-408. PubMed ID: 2982998
[No Abstract] [Full Text] [Related]
52. The effect of aurothiomalate on the oxidative burst of polymorphonuclear leukocytes varies with the quantity of drug in myocrisin ampoules.
Rudkowski R; Graham GG; Ziegler JB; Champion GD
J Rheumatol; 1991 May; 18(5):666-71. PubMed ID: 1907663
[TBL] [Abstract][Full Text] [Related]
53. Interferon as an antiviral agent in vivo: quantitative and temporal aspects of the protection of mice against Semliki Forest virus.
Finter NB
Br J Exp Pathol; 1966 Aug; 47(4):361-71. PubMed ID: 5917346
[No Abstract] [Full Text] [Related]
54. Requirement for macrophages for interferon to be effective against encephalomyocarditis virus infection of mice.
Stebbing N; Dawson KM; Lindley IJ
Infect Immun; 1978 Jan; 19(1):5-11. PubMed ID: 203537
[TBL] [Abstract][Full Text] [Related]
55. Neonatal infection of mice with lactate dehydrogenase-elevating virus results in suppression of humoral antiviral immune response but does not alter the course of viraemia or the polyclonal activation of B cells and immune complex formation.
Rowland RR; Even C; Anderson GW; Chen Z; Hu B; Plagemann PG
J Gen Virol; 1994 May; 75 ( Pt 5)():1071-81. PubMed ID: 8176369
[TBL] [Abstract][Full Text] [Related]
56. Sequence analysis of the avirulent, demyelinating A7 strain of Semliki Forest virus.
Tarbatt CJ; Glasgow GM; Mooney DA; Sheahan BJ; Atkins GJ
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1551-7. PubMed ID: 9225028
[TBL] [Abstract][Full Text] [Related]
57. [Immunosuppressive effect of L-asparaginase. Cellular and humoral studies].
Emmerling P; Finger H
Z Immunitatsforsch Allerg Klin Immunol; 1970 Nov; 140(5):472-81. PubMed ID: 4249814
[No Abstract] [Full Text] [Related]
58. Infection, interaction and the expression of virulence by defined strains of Semliki forest virus.
Bradish CJ; Allner K; Maber HB
J Gen Virol; 1972 Sep; 16(3):359-72. PubMed ID: 5079088
[No Abstract] [Full Text] [Related]
59. Pathogenesis of Semliki Forest virus encephalitis.
Fazakerley JK
J Neurovirol; 2002 Dec; 8 Suppl 2():66-74. PubMed ID: 12491154
[TBL] [Abstract][Full Text] [Related]
60. The pathogenicity of the M9 mutant of Semliki Forest virus in immune-compromised mice.
Gates MC; Sheahan BJ; Atkins GJ
J Gen Virol; 1984 Jan; 65 ( Pt 1)():73-80. PubMed ID: 6319575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
